Hemony Pharmaceutical Co., Ltd. has gradually grown into a whole industrial chain enterprise that integrates R&D, manufacturing and sales of drugs and medical devices. Registered in Lhasa Economic and Technological Development Zone, Tibet, Hemony is also headquartered in Shanghai and Chongqing, with subsidiaries located in Hong Kong, Taiwan, Germany, Switzerland and other countries and regions.

As a pioneer to practice the Marketing Authorization Holder (MAH) system in domestic China, Hemony has a wealth of experience in merging and acquiring mature pharmaceutical assets from multinational pharmaceutical companies. In recent years, our company has merged and acquired the superior products of numerous multinational pharmaceutical corporations, including Alvogen's Triazolone Hydrochloride Tablets in the United States, Novartis' Baclofen Tablets in Switzerland, Wyeth's Multivitamin Elemental Tablets in the United States, Takeda's Calcium Carbonate D3 Chewable Tablets in Japan, STADA's Lipoic Acid Injection in Germany, Herbrand's Propylthiouracil Tablets in Germany, etc.

The corporation has established a trend of concurrent development of prescription and over-the-counter medications after years of development. Prescription drugs mainly target the fields of psychiatry, orthopedics, otolaryngology, pediatrics, obstetrics and gynecology, as well as other disease areas, with a sales team with differentiated coverage in urban hospitals, county medical institutions and grassroots public hospitals; Moreover, OTC includes Calcichew®D, Haiweibao®, Hailichang®, Lactéol® and other high-quality branded products, covering multiple channels such as KA chains, small and medium-sized chains and specialty clinics.

With the mission of “All Efforts for Health”, Hemony is committed to becoming a globally well-known life science company. Upholding the core values of “Aspiration, Striving, Innovation, Inclusiveness and Integrity”, Hemony strives to provide people with high quality pharmaceutical products and services.